A Case Report of Three Guillain-Barré Syndrome During SARS-CoV-2 Pandemic: Promising Outcome in a Patient with History of Multiple Sclerosis
Abstract
Neurologic complications in patients with coronavirus disease 19 (COVID-19) are common particularly in hospitalized patients. Guillain–Barré syndrome (GBS) is a rare complication of COVID-19. Most patients with GBS and COVID-19 presented with progressive, ascending limb weakness evolving over one to four days. There are some reported cases of GBS, mostly in form of case reports or case series, and also a comprehensive review on this topic. However, none of these cases experienced multiple sclerosis (MS) as an underlying disease. So, in this manuscript we reported three cases of COVID-19 induced GBS; one of them with history of MS and promising outcome after receiving five session of plasmaphresis and corticosteroid therapy.
1.Baig AM. Neurological manifestations in COVID‐19 caused by SARS‐CoV‐2. CNS Neurosci Ther. 2020; 26: 499-501.
2.Mao L, Jin H, Wang M, et al. Neurological manifestations in COVID‐19 caused by SARS‐CoV‐2. JAMA Neural. 2020; 77(6): 683-90.
3.Helms J, Kremer S, Merdji H, et al., Neurologic Features in Severe SARS-CoV-2 Infection. N Engl J Med 2020; 382: 2268-70.
4.Abu-Rumeileh S, Abdelhak A, Foschi M, Tumani H, Otto M. Guillain–Barré syndrome spectrum associated with COVID‑19: an up‑to‑date systematic review of 73 cases. J Neurol 2020;25: 1-38.
5.Farzi MA, Ayromlou H, Jahanbakhsh N, et al. Guillain-Barré syndrome in a patient infected with SARS-CoV-2, a case report. J Neuroimmunol 2020; 346:577294.
6.Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet 2016; 388: 717-27.
7.Kim JE, Heo JH, Kim HO, et al. Neurological complications during treatment of Middle East respiratory syndrome. J Clin Neurol. 2017; 13(3), 227–33.
8.Zhao H, Shen D, Zhou H, Liu J, Chen S. Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? Lancet Neurol. 2020; 19(5):383-4.
9.Jin JM, Bai P, He W, et al. Gender differences in patients with COVID-19: focus on severity and mortality. Front Public Health. 2020; 8:152.
10. Dirlikov E, Major CG, Medina NA, et al. Clinical features of Guillain-Barré syndrome with vs without zika virus infection, Puerto Rico, 2016. JAMA Neurol. 2018; 75(9):1089–97.
11.Bracaglia M, Naldi I, Govoni A, Vantura DB, De Massis P. Acute inflammatory demyelinating polyneuritis in association with an asymptomatic infection by SARS-CoV-2. J Neurl. 2020; 1-3.
12.Oguz-Akarsu E, Ozpar R, Mirzayev H, et al. Guillain-Barré syndrome in a patient with minimal symptoms of COVID-19 infection. Muscle Nerve. 2020; 10.1002/mus.26992.
13.Paterson RW, Brown RL, Benjamin L, et al. The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. Brain. 2020; 143(10):3104-20.
14.Juliao Caamaño DS, Alonso Beato R. Facial diplegia, a possible atypical variant of Guillain-Barré Syndrome as a rare neurological complication of SARS-CoV-2. J Clin Neurosci. 2020; 77: 230-2.
2.Mao L, Jin H, Wang M, et al. Neurological manifestations in COVID‐19 caused by SARS‐CoV‐2. JAMA Neural. 2020; 77(6): 683-90.
3.Helms J, Kremer S, Merdji H, et al., Neurologic Features in Severe SARS-CoV-2 Infection. N Engl J Med 2020; 382: 2268-70.
4.Abu-Rumeileh S, Abdelhak A, Foschi M, Tumani H, Otto M. Guillain–Barré syndrome spectrum associated with COVID‑19: an up‑to‑date systematic review of 73 cases. J Neurol 2020;25: 1-38.
5.Farzi MA, Ayromlou H, Jahanbakhsh N, et al. Guillain-Barré syndrome in a patient infected with SARS-CoV-2, a case report. J Neuroimmunol 2020; 346:577294.
6.Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet 2016; 388: 717-27.
7.Kim JE, Heo JH, Kim HO, et al. Neurological complications during treatment of Middle East respiratory syndrome. J Clin Neurol. 2017; 13(3), 227–33.
8.Zhao H, Shen D, Zhou H, Liu J, Chen S. Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? Lancet Neurol. 2020; 19(5):383-4.
9.Jin JM, Bai P, He W, et al. Gender differences in patients with COVID-19: focus on severity and mortality. Front Public Health. 2020; 8:152.
10. Dirlikov E, Major CG, Medina NA, et al. Clinical features of Guillain-Barré syndrome with vs without zika virus infection, Puerto Rico, 2016. JAMA Neurol. 2018; 75(9):1089–97.
11.Bracaglia M, Naldi I, Govoni A, Vantura DB, De Massis P. Acute inflammatory demyelinating polyneuritis in association with an asymptomatic infection by SARS-CoV-2. J Neurl. 2020; 1-3.
12.Oguz-Akarsu E, Ozpar R, Mirzayev H, et al. Guillain-Barré syndrome in a patient with minimal symptoms of COVID-19 infection. Muscle Nerve. 2020; 10.1002/mus.26992.
13.Paterson RW, Brown RL, Benjamin L, et al. The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. Brain. 2020; 143(10):3104-20.
14.Juliao Caamaño DS, Alonso Beato R. Facial diplegia, a possible atypical variant of Guillain-Barré Syndrome as a rare neurological complication of SARS-CoV-2. J Clin Neurosci. 2020; 77: 230-2.
| Files | ||
| Issue | Vol 10, No 3 (Summer 2022) | |
| Section | Case Report(s) | |
| DOI | https://doi.org/10.18502/jpc.v10i3.10800 | |
| Keywords | ||
| Guillain–Barré Syndrome COVID-19 Multiple Sclerosis | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Ghahremani A ali, Bigdeli A, Salarbashi D, Shakouri P, Elyasi S. A Case Report of Three Guillain-Barré Syndrome During SARS-CoV-2 Pandemic: Promising Outcome in a Patient with History of Multiple Sclerosis. J Pharm Care. 2022;10(3):183-187.
